Holen Sie sich die Stockscreener-App
2.52
0.80%
0.02
Handel nachbörslich:
2.53
0.010
+0.40%
Schlusskurs vom Vortag:
$2.50
Offen:
$2.54
24-Stunden-Volumen:
1.18M
Relative Volume:
0.49
Marktkapitalisierung:
$226.60M
Einnahmen:
$32.31M
Nettoeinkommen (Verlust:
$-237.09M
KGV:
-0.875
EPS:
-2.88
Netto-Cashflow:
$-219.11M
1W Leistung:
-4.91%
1M Leistung:
-1.56%
6M Leistung:
+43.18%
1J Leistung:
-28.00%
1-Tages-Spanne:
$2.39
$2.54
1-Wochen-Bereich:
$2.39
$2.72
52-Wochen-Spanne:
$0.9101
$4.12
Editas Medicine Inc Stock (EDIT) Company Profile
Firmenname
Editas Medicine Inc
Sektor
Branche
Telefon
617-401-9000
Adresse
11 HURLEY ST., CAMBRIDGE, MA
Vergleichen Sie EDIT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EDIT
Editas Medicine Inc
|
2.52 | 222.10M | 32.31M | -237.09M | -219.11M | -2.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Editas Medicine Inc Stock (EDIT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-12-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-12-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2024-12-13 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-13 | Herabstufung | Truist | Buy → Hold |
| 2024-12-11 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-11-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-11-04 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-08-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-05-09 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-24 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-10-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-10-17 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-29 | Hochstufung | Stifel | Hold → Buy |
| 2023-06-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-13 | Eingeleitet | Citigroup | Neutral |
| 2022-12-06 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-11-18 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-09-29 | Eingeleitet | BofA Securities | Neutral |
| 2021-10-19 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-09-24 | Eingeleitet | Stifel | Hold |
| 2021-09-10 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-08-09 | Hochstufung | Truist | Hold → Buy |
| 2021-08-05 | Hochstufung | Evercore ISI | Underperform → Outperform |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-04 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2021-04-16 | Eingeleitet | Goldman | Sell |
| 2021-03-22 | Eingeleitet | Credit Suisse | Outperform |
| 2021-03-01 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2021-02-26 | Herabstufung | Truist | Buy → Hold |
| 2021-01-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-01-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-12-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-11-03 | Eingeleitet | Robert W. Baird | Underperform |
| 2020-06-18 | Fortgesetzt | SunTrust | Buy |
| 2020-02-21 | Eingeleitet | Wells Fargo | Equal Weight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-10 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-21 | Eingeleitet | Raymond James | Outperform |
| 2018-05-15 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-02-13 | Eingeleitet | CLSA | Underperform |
| 2018-01-23 | Hochstufung | SunTrust | Hold → Buy |
| 2017-07-14 | Eingeleitet | SunTrust | Hold |
| 2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-08-10 | Hochstufung | Jefferies | Hold → Buy |
| 2016-06-02 | Eingeleitet | Jefferies | Hold |
| 2016-02-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-29 | Eingeleitet | JP Morgan | Neutral |
| 2016-02-29 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Editas Medicine Inc Aktie (EDIT) Neueste Nachrichten
Editas Medicine (NASDAQ:EDIT) Shares Cross Below 50 Day Moving AverageWhat's Next? - MarketBeat
Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
What are Editas Medicine Inc.’s technical support levelsJuly 2025 Drop Watch & Low Risk Growth Stock Ideas - khodrobank.com
Editas Medicine price target raised to $4 from $3 at Wells Fargo - TipRanks
Activity Recap: How does Editas Medicine Inc. score in quality rankingsDay Trade & Free Accurate Trade Setup Notifications - khodrobank.com
what the charts say about editas medicine inc. todayQuarterly Profit Summary & Smart Allocation Stock Reports - Newser
Is now the right time to enter Editas Medicine Inc.Dividend Hike & Low Drawdown Investment Ideas - khodrobank.com
How to track smart money flows in Editas Medicine Inc.Weekly Trade Review & Verified Technical Signals - Newser
Is it time to cut losses on Editas Medicine Inc.2025 Institutional Moves & Risk Controlled Swing Trade Alerts - Newser
Statistical indicators supporting Editas Medicine Inc.’s strengthDollar Strength & AI Enhanced Execution Alerts - Newser
Using data models to predict Editas Medicine Inc. stock movementTake Profit & Weekly High Potential Alerts - Newser
Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol - TradingView
Is Editas Medicine Inc. forming a reversal patternTrade Volume Summary & Weekly Stock Breakout Alerts - Newser
What machine learning models say about Editas Medicine Inc.Weekly Stock Report & High Accuracy Swing Trade Signals - Newser
Predicting Editas Medicine Inc. trend using moving averages2025 Top Gainers & Smart Allocation Stock Tips - Newser
Editas Medicine’s Strategic Milestone in In Vivo Gene Editing: A Catalyst for Long-Term Value - AInvest
Chart based exit strategy for Editas Medicine Inc.Swing Trade & Reliable Trade Execution Plans - Newser
Macro Review: Is Editas Medicine Inc.’s ROE strong enoughWeekly Profit Report & Growth Oriented Trading Recommendations - khodrobank.com
How to escape a deep drawdown in Editas Medicine Inc.2025 Price Action Summary & Low Drawdown Trading Strategies - Newser
Applying big data sentiment scoring on Editas Medicine Inc.Earnings Beat & Intraday High Probability Alerts - Newser
Evaluating Editas Medicine Inc. with trendline analysisJuly 2025 Breakouts & AI Driven Stock Price Forecasts - Newser
Does Editas Medicine Inc. stock have upside surprise potentialTrade Performance Summary & Daily Growth Stock Investment Tips - khodrobank.com
When is the best time to exit Editas Medicine Inc.Quarterly Growth Report & Daily Entry Point Alerts - Newser
Using Ichimoku Cloud for Editas Medicine Inc. technicals2025 Macro Impact & Safe Entry Momentum Stock Tips - Newser
Editas Medicine shares rise 1.30% after-hours after unveiling lead development candidate EDIT-401. - AInvest
Editas Medicine shares fall 1.75% intraday after announcing EDIT-401 as lead in vivo development candidate. - AInvest
What the charts say about Editas Medicine Inc. today2025 Earnings Surprises & Technical Pattern Recognition Alerts - Newser
Using portfolio simulators with Editas Medicine Inc. includedDip Buying & Verified Swing Trading Watchlist - Newser
Editas turns to cholesterol therapy, becoming latest gene editing company to pivot to more common diseases - Endpoints News
Editas Medicine : Lead In Vivo Development Candidate Webinar Presentation (8e4429) - MarketScreener
Editas Medicine nominates lead in vivo development candidate - BioWorld MedTech
Editas Medicine’s Strategic Pivot to In Vivo Gene Editing: A Catalyst for Cardiovascular Innovation and Valuation Growth - AInvest
Editas Medicine Incnominates Edit-401 as lead in vivo candidate - MarketScreener
Editas Medicine nominates EDIT-401 as lead in vivo development candidate - TipRanks
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate - GlobeNewswire
Editas Medicine selects EDIT-401 as lead in vivo development candidate - StreetInsider
90% Cholesterol Reduction: Editas Medicine's New Gene Therapy EDIT-401 Shows Dramatic Results in Primates - Stock Titan
Can Editas Medicine Afford to Invest in Growth? - AInvest
Can Editas Medicine (NASDAQ:EDIT) Afford To Invest In Growth? - Yahoo Finance
Gene Editing Market to Surpass USD 15.46 Billion by 2032, Fueled by Breakthroughs in CRISPR Technology and Precision Medicine – SNS Insider - GlobeNewswire Inc.
Can Editas Medicine Inc. weather a recessionDay Trade & Detailed Earnings Play Strategies - khodrobank.com
How volatile is Editas Medicine Inc. stock2025 Risk Factors & High Accuracy Swing Trade Signals - khodrobank.com
Is Editas Medicine Inc. forming a bottoming baseWall Street Watch & Reliable Intraday Trade Alerts - Newser
Analyzing drawdowns of Editas Medicine Inc. with statistical toolsShare Buyback & Technical Entry and Exit Tips - Newser
What’s the beta of Editas Medicine Inc. stockAnalyst Upgrade & High Accuracy Trade Signal Alerts - khodrobank.com
Is Editas Medicine Inc. a candidate for recovery playMarket Weekly Review & Daily Growth Stock Investment Tips - Newser
Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data - MSN
Real time scanner hits for Editas Medicine Inc. explainedWeekly Earnings Recap & Fast Exit/Entry Strategy Plans - Newser
How to use Fibonacci retracement on Editas Medicine Inc.Portfolio Performance Summary & AI Driven Price Forecasts - Newser
Is Editas Medicine Inc. stock entering bullish territoryMarket Risk Report & Low Risk High Win Rate Stock Picks - Newser
Trendline Breach Raises Concern for Editas Medicine Inc. Investors getLinesFromResByArray error: size == 0 - kangso.co.kr
Finanzdaten der Editas Medicine Inc-Aktie (EDIT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):